Epigenomics · 2021 · 20 citations · 39 references
MedicineMolecular MedicineOncologyEarly DetectionGastroenterologyGastrointestinal OncologyBiomarker ValidationCancer BiomarkersCancer Molecular DiagnosticsGastric CancerGastric DiseasesGastrointestinal PathologyAtrophic GastritisBiomarkers Of Gastric CancerCancer Biomarker DetectionCancer Epigenetic BiomarkersGastric PathologyGastrointestinal Disease BiomarkersProspective Cohort DataProtein Biomarker Validation
Aim: This study aimed to validate a combination of mSEPT9, mRNF180 and CA724 for gastric cancer (GC) detection. Patients & methods: The performance of mSEPT9, mRNF180 and CA724 was examined in a prospective cohort study with 518 participants (151 with GC, 56 with atrophic gastritis, 87 with other gastrointestinal diseases and 224 with no evidence of disease). Results: mSEPT9, mRNF180 or CA724 alone detected 48.3, 37.1 and 43.1% of GC, respectively. The combination of mSEPT9 and mRNF180 detected 60.3% of GC, and the combination of all three markers detected 68.6% of GC. The detection sensitivity of mSEPT9 and mRNF180 was significantly higher for gastric body and in elder subjects. mSEPT9 was correlated with poorer GC survival. Conclusion: The combination of mSEPT9, mRNF180 and CA724 was adequately sensitive for GC detection. The blood mSEPT9 was predictive for GC prognosis.
39
Cancer statistics in China, 2015
Wanqing Chen, Rongshou Zheng, Peter D. Baade et al. · CA A Cancer Journal for Clinicians · 2016 · 18K citations · Full text
DNA Methylation Biomarkers for Blood-Based Colorectal Cancer Screening
Catherine Lofton–Day, Fabian Model, Theo deVos et al. · Clinical Chemistry · 2007 · 493 citations
Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer
Jorja D Warren, Wei Xiong, Ashley M. Bunker et al. · BMC Medicine · 2011 · 444 citations · Full text